Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. O...
Saved in:
Main Author: | Stefan D. Anker |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/dd839f2ab3bf4e1e9d6388f31d4cd802 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heart failure in diabetes: From an increased risk to a treatment target
by: Eberhard Standl
Published: (2018) -
Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
by: Yury Ivanovich Suntsov
Published: (2012) -
Role of incretin based therapies in the treatment of diabetic kidney disease
by: Paola Fioretto, et al.
Published: (2018) -
Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
by: Gagik R. Galstyan, et al.
Published: (2016) -
Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
by: Sergey V. Kakorin, et al.
Published: (2016)